The FDA PMA submission cadence (modules expected through Q2 2027) sets a clear catalyst timeline. Monitor for completion of all four modules and FDA feedback, which could trigger major price moves. The ATM termination is credit-positive for existing shareholders, removing a dilution overhang.
Price Chart
Executive Summary
Envoy Medical reported Q2 2026 results with a slim net revenue of $51K (down from $78K YoY), a net loss attributable to common stockholders of $7.27M ($0.07/share vs $0.32/share YoY on massively higher share count), and cash of $19.68M. The key positive was the submission of the first module of its modular PMA application to the FDA for the Acclaim cochlear implant and the termination of the ATM facility (removing future dilution). However, pre-revenue burn shows no path to commercial revenue without FDA approval ~2027+, keeping the stock binary on regulatory outcome.
Key Financial Metrics
Key Facts
- Net revenue was $51K for Q2 2026, down from $78K in Q2 2025 (a 34.6% decline).
- Net loss attributable to common stockholders was $7.27M ($0.07/share) vs $6.94M ($0.32/share) in Q2 2025.
- Cash balance was $19.68M as of June 30, 2026, down from $25.25M at March 31, 2026.
- First of four modules of the modular PMA application for the Acclaim cochlear implant was submitted to the FDA; final module targeting Q2 2027.
- At-the-market (ATM) equity facility of up to $15M was terminated, removing future potential stock dilution.
- Positive 12-month data from Stage 1: mean CNC word recognition score improved from 15.2% to 53.2%, a 38.0 percentage point improvement.
- R&D expenses were $3.13M in Q2 2026, up from $2.49M in Q2 2025, driven by clinical trial and PMA submission costs.
- Operating cash flow was negative $11.52M for the first six months of 2026.
Financial Impact
No material financial impact from current operations. Cash burn rate ~$5.8M/quarter; runway into mid-2027 if burn rate holds.
Risk Factors
- FDA denial of the Acclaim cochlear implant's PMA would materially impair the company's ability to generate revenue.
- Cash burn of ~$6M/quarter may require additional capital before commercialization if PMA submission or approval is delayed beyond current cash runway.
- The 12-month Stage 1 data (n=10) may not be representative of Stage 2 results or the full cohort's primary endpoint outcome.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-087221 |
| Document: ea0301372-8k_envoy.htm | 0001213900-26-087221 |
| Document: 0001213900-26-087221-index-headers.html | 0001213900-26-087221 |
| Document: 0001213900-26-087221-index.html | 0001213900-26-087221 |
| Document: 0001213900-26-087221.txt | 0001213900-26-087221 |
| 8-K Data (Synthetic) | 0001213900-26-087221 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $5.11 | awaiting T+60 | — | $6.50 (−27.22%) |
Oct 7, 2026 20d ago | 8-K | $0.6534 | awaiting T+60 | — | $6.50 (+894.90%) |
Sep 2, 2026 7w ago | DEFA14A | $0.7301 | awaiting T+60 | — | $6.50 (+790.38%) |
Aug 10, 2026 11w ago | 8-K | $0.7700 | awaiting T+60 | — | $6.50 (+744.25%) |
Jun 30, 2026 16w ago | 8-K | $0.7901 $0.7161 | ▼ −9.37% | ▼ −12.24% | $6.50 (+722.77%) |
Jun 17, 2026 18w ago | EFFECT | $0.6544 $0.7402 | ▼ −13.11% | ▼ −9.96% | $6.50 (−893.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers